On Feb. 2, 2022, the U.S. Food and Drug Administration announced it had approved the first generic of Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use vials (eye drops) to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (commonly known as dry eye).

Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.